跳至主要内容
临床试验/JPRN-UMIN000010765
JPRN-UMIN000010765已完成2 期

Additive effect of zoledronic acid on hormone-sensitive prostate cancer patients with bone metastasis treated by hormonal therapy: a prospective, multicenter study - Additive effect of zoledronic acid on hormone-sensitive prostate cancer patients with bone metastasis treated by hormonal therapy: a prospective, multicenter study

Department of Urology, Saitama Medical Center, Saitama Medical University0 个研究点目标入组 100 人开始时间: 2013年5月20日最近更新:
适应症

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
100

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
20years-old 至 ot applicable(—)
性别
Male

入选标准

  • 未提供

排除标准

  • Patients 1) do not meet the inclusion criteria. 2) have an allergy to bisphosphonates including zoledronic acid. 3) required an urgent radiation therapy for bone metastasis based on symptoms described below: unmanageable pain, spinal cord paralysis, etc. 4) have a treatment history with a bisphosphonate (excluding bisphosphonates taken orally). 5) have an uncontrollable pleural or pericardial effusion. 6) have a brain metastasis with symptoms. 7) have a heavy infection. 8) under or planned an invasive dental treatment. 9) have an interstitial pneumonitis or pulmonary fibrosis. 10) have an active cancer except prostate cancer: cancer free duration <= 3 years. 11) have a myocardial infarction within 6 months. 12) have severe complications: cardiovascular disease, hepatic dysfunction, or coagulation disorders, etc. 13) have mental disorders or neurological symptoms. 14) disqualified by a doctor in charge.

研究者

发起方
Department of Urology, Saitama Medical Center, Saitama Medical University

相似试验